H.-J. Stellbrink

Learn More
Purpose of study S/GSK1349572, a next-generation HIV-1 integrase inhi-bitor, has previously demonstrated potent antiviral activity in Phase 2a with once-daily, unboosted dosing. SPRING-1 is an ongoing dose-ranging study designed to select a dose to for Phase 3 evaluation. Methods SPRING-1 is a Phase 2b, multicentre, partially-blinded study in therapy-naïve(More)
Background: Toll-like receptors (TLRs) are transmembrane receptors that activate cells of the innate immune systems upon recognition of pathogen-associated molecular patterns. The TLR4 is an essential component of the innate immune response to various microorganisms. We investigated the impact of TLR4 polymorphism on development of opportunistic diseases in(More)
Objective To analyze the characteristics and outcome of acute Hepatitis C and the risk of reinfection following SVR in HIV+ MSM. Methods Database analysis of the ICH cohort (n=4851), analysis restricted to MSM seen between 1/2002 and 6/2010. Acute HCV infection was defined as a sudden rise in liver enzymes with a positive HCV PCR and/or a newly positive HCV(More)
  • 1